*From the Authors*:

We thank Puxeddu and colleagues for their interest in our paper and for opening a dialogue regarding the role of CD71-expressing airway macrophages (AMs) in interstitial lung disease (ILD) ([@bib1]). Indeed, it is interesting that the authors found a similar population of CD71^−^ AMs in a second cohort of patients with idiopathic pulmonary fibrosis (IPF), further validating our findings. The authors describe a level of CD71^−^AMs in a group of patients with non-IPF ILD comparable to that observed in patients with IPF. These data raise the question of whether CD71^−^ AMs may be an important pathogenic component of IPF as well as other fibrotic lung diseases.

To determine whether the proportions of CD71-expressing AMs were altered during non-IPF ILD, we examined BAL samples from a cohort of patients with hypersensitivity pneumonitis (*n* = 18), respiratory bronchiolitis--associated ILD (*n* = 2), sarcoidosis (*n* = 2), or undifferentiated connective tissue disease (*n* = 5), and used a multicolor flow-cytometry gating strategy identical to that described in our initial publication ([@bib1]). We found that in patients with non-IPF ILD, there was an increase in the proportion of CD71^−^ AMs compared with healthy control subjects, and furthermore, the proportions of these populations were similar to those found in patients with IPF ([Figure 1](#fig1){ref-type="fig"}). One of the key findings of our original study is that CD71^−^ AM status was an independent predictor of survival in patients with IPF. Importantly, in this non-IPF group, there was only one death over the period investigated, so it was not possible to investigate the relationship between CD71^−^ AMs and mortality in this cohort.

![Proportions of CD71^−^ airway macrophages (AMs) in BAL from healthy subjects (*n* = 11), patients with idiopathic pulmonary fibrosis (IPF) (*n* = 75), and patients with non-IPF interstitial lung disease (ILD) (*n* = 23). \*\*\**P* \< 0.001 and \*\*\*\**P* \< 0.0001, Mann-Whitney *U* test. n.s. = not significant.](rccm.201907-1347LE_f1){#fig1}

We agree that further studies on the role of CD71 in the pathogenesis of fibrotic lung disease are needed to confirm our observations, and we thank the authors for adding to our findings.
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